NEW YORK (TheStreet) -- CHANGE IN RATINGS
Abercrombie & Fitch was initiated with a buy rating at Nomura. $43 price target. Management is taking action to combat weaker sales, Nomura said.
BioMed Realty Trust was downgraded to hold at TheStreet Ratings.
Community Health Systems was downgraded at Citigroup to neutral from buy and given a $42 price target. Third quarter will be sequentially weaker, and the HMA acquisition will add leverage and operational risk, Citigroup said.
Domino's Pizza was initiated with a buy rating at Keybanc. $70 price target. Company can continue to deliver solid growth and deserves a premium valuation, Keybanc said.
EOG Resources was upgraded at Morgan Stanley to overweight. $200 price target. Company is growing inventory and free cash flow is at an inflection point, though the company trades at a discount to its peers, Morgan Stanley said.
Eaton was upgraded at Morgan Stanley to overweight from neutral. $76 price target. $5 EPS in 2014 is in play and favorable risk/reward, Morgan Stanley said.
Expedia was upgraded to buy at Lazard Capital Markets. $60 price target. Recent checks show solid growth and Travelocity may exceed expectations, Lazard Capital Markets said.
Gap was initiated with a neutral rating at Nomura. $42 price target. Total sales volume remains below 2004 levels, Nomura said.
HollyFrontier was downgraded at Morgan Stanley to equal weight. Valuation call, based on a $53 price target, Morgan Stanley said.
IAC/InterActiveCorp downgraded at Canaccord Genuity to hold from buy. Valuation call, based on a $56 price target, Canaccord Genuity said.
Moody's was initiated with an outperform rating at William Blair. Legal and regulatory risks are easing, and Europe and structured finance market should drive growth, William Blair said.
NetApp was upgraded at UBS to buy from neutral and given a $50 price target. The company is gaining share and the product cycle will be a benefit, UBS said.
Outerwall was downgraded at Pacific Crest to underperform from sector perform. DVD rentals will likely continue to be hurt by a technology transition, Pacific Crest said. Fair value is near $32.
Rockwood was downgraded at Deutsche Bank to hold from buy. $70 price target. Valuation call, as the stock is up 29% year to date, Deutsche Bank said.
Salix Pharmaceuticals was upgraded at Leerink Swann to outperform from market perform. $80 price target. Outlook is improving for Xifaxan, Leerink Swann said.
South Jersey Industries was downgraded to hold at TheStreet Ratings.
Cimarex was upgraded at Morgan Stanley to overweight. $105 price target. Permian basin could drive growth for the next several years, Morgan Stanley said.
STOCK COMMENTS / EPS CHANGES
Comerica estimates, price target were lowered at BMO Capital Markets. Estimates were also cut, given lower realized loan growth, said BMO Capital Markets. Market Perform rating.
The Cooper Companies numbers were raised at Jefferies. Shares are now seen reaching $130. Estimates were also increased on another quarter of above-market CVI growth. Hold rating.
Ford estimates were raised at Jefferies through 2014. U.S. market remains healthy and company has production flexibility, Jefferies said. Buy rating and $20 price target.
Facebook numbers were raised at Sterne Agee. Shares are now seen reaching $50. Estimates were also increased on conitnued success of mobile, Sterne Agee said. Buy rating.
Harley Davidson price target was raised at Citigroup to $72. Sales are accelerating, said Citigroup.
Las Vegas Sands numbers were raised at Citigroup. Earnings estimates were increased given SCL share gains, said Citigroup. Price target goes to $72.
Health Management Associates estimates were cut at Citigroup. Earnings estimates were reduced based on a sequentially weaker third quarter and acquisition distractions, said Citigroup. Price target is $15.
Mattress Firm numbers were reduced at UBS. Earnings estimates were cut given weakness at vendors and tempering sales. Price target is reduced to $40.
>To submit a news tip, email: firstname.lastname@example.org.
Follow TheStreet on Twitter and become a fan on Facebook.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.
- Investment & Company Information
- Morgan Stanley